title: Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
abstract: BACKGROUND
  To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment.
  
  
  METHODS
  This study retrospectively evaluated 202 patients with locally advanced ESCC treated at Shandong Cancer Hospital between January 2009 and December 2013. All the patients initially received dCRT, including platinum and paclitaxel or 5-fluorouracil, with concurrent 1.8 or 2 Gy/fraction radiation (total dose, 54-60 Gy). The patient population was divided into two treatment groups: 105 patients who received the cisplatinum/paclitaxel regimen were allocated to group A, and 97 patients who received the cisplatinum/5-fluorouracil regimen were allocated to group B. We compared the progression-free survival (PFS) and overall survival (OS) by various clinical variables, including prior treatment characteristics, major toxicities (mainly in grade 3 and 4 hematological), and response to dCRT. We used the receiver operating curve analysis to determine the optimal cutoff value of clinical stage and radiation dose. The Kaplan-Meier method was used for survival comparison and Cox regression for multivariate analysis.
  
  
  RESULTS
  Median PFS and OS in group A were significantly better compared with group B (median PFS, 15.9 versus 13.0 months, P=0.016 and median OS, 33.9 versus 23.1 months, P=0.014, respectively). The 1- and 2-year survival rates of the two groups were 82.9% versus 76.3%, and 61.9% versus 47.6%, respectively. The complete response and response rate were 17.1% versus 7.2% (P=0.032) and 52.4% versus 30.9% (P=0.042) in group A and B, respectively. Meanwhile, group B was associated with a significantly lower rate of grade 3/4 overall toxicity than group A (P=0.039).
  
  
  CONCLUSIONS
  Our data showed that patients with locally advanced ESCC in group A had longer PFS and OS compared with group B. Cisplatinum/paclitaxel can be considered a good candidate chemotherapy regimen for patients with locally advanced ESCC who are being treated with nonsurgical therapy.
authors.affiliation: School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences.
authors.forename: Guofang
authors.initials: G
authors.lastname: Hu
authors.affiliation: Department of Oncology, Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: Zhehai
authors.initials: Z
authors.lastname: Wang
authors.affiliation: School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences.
authors.forename: Qingqing
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences.
authors.forename: Ning
authors.initials: N
authors.lastname: Tang
authors.affiliation: Department of Oncology, Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
authors.affiliation: Department of Oncology, Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: Liyan
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Oncology, Shandong Cancer Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Han
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil
keywords: complete response; definitive chemoradiotherapy; esophageal carcinoma; survival; toxicity